AcelRx Pharmaceuticals

375 articles with AcelRx Pharmaceuticals

• AcelRx Pharmaceuticals Reports Second Quarter 2020 Financial Results

  8/10/2020

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its second quarter 2020 financial results.

• AcelRx to Host Second Quarter 2020 Financial Results Call and Webcast on Monday, August 10th, 2020

  8/3/2020

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close on Monday, August 10, 2020

• AcelRx Announces Exclusive Distribution and Promotion Partnership for DSUVIA®

  7/23/2020

  AcelRx expands DSUVIA commercial opportunity with an established, leading partner to advance oral surgical care

• AcelRx Announces $10 Million Common Stock Offering Priced At The Market

  7/23/2020

  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today annou

• AcelRx Pharmaceuticals Announces It Will Not Further Revise Its Offer to Acquire Tetraphase

  6/3/2020

  AcelRx Pharmaceuticals, Inc. announced that it does not intend to revise further its offer under the terms of its previously announced agreement to acquire Tetraphase Pharmaceuticals, Inc., and it expects the agreement to be terminated by Tetraphase.

• AcelRx Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

  6/1/2020

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management will be providing an overview of the business and company updates at the Jeffries Virtual Healthcare Conference to be held June 2 at 1:30 p.m. ET

• Tetraphase Announces Receipt of Amended Melinta Proposal, Determination of Superior Offer and Notice to AcelRx

  5/28/2020

  Tetraphase Pharmaceuticals, Inc. announced that its Board of Directors has received a revised proposal from Melinta Therapeutics, Inc. amending its prior proposal to acquire the Company, and has determined that the Amended Melinta Proposal is a “Superior Offer” under the terms of the Agreement and Plan of Merger, dated March 15, 2020 and amended on May 27, 2020, to which the Company is a party with AcelRx Pharmaceuticals, Inc. and its merger subsidiary.

• AcelRx Pharmaceuticals Announces Revised Merger Agreement with Tetraphase

  5/27/2020

  Under revised terms, AcelRx to acquire Tetraphase for $30.0 million in stock and cash, plus an additional $14.5 million in CVRs Continues to believe Tetraphase acquisition complements AcelRx's commercial strategy and will deliver long-term shareholder value Co-promotion agreement for XERAVA and DSUVIA proceeding well with teams already integrated

• AcelRx Pharmaceuticals Reports First Quarter 2020 Financial Results

  5/11/2020

  Expects to See Strong Volume of Orders from U.S. Military Following Milestone C Approval for DSUVIA

• AcelRx to Host First Quarter 2020 Financial Results Call and Webcast on Monday, May 11th, 2020

  5/4/2020

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release first quarter financial results after market close on Monday, May 11, 2020.

• AcelRx Announces DSUVIA® Milestone C Approval and Provides Business Update

  4/30/2020

  AcelRx Pharmaceuticals, Inc. announced that DSUVIA achieved Milestone C approval, a decision that clears the path for DSUVIA to be included in military sets, kits and outfits.

• Tetraphase Pharmaceuticals and AcelRx Pharmaceuticals Enter into Definitive Merger Agreement

  3/16/2020

  AcelRx to Acquire Tetraphase in an all-stock transaction

• AcelRx Pharmaceuticals to Acquire Tetraphase Pharmaceuticals

  3/16/2020

  AcelRx to acquire Tetraphase in a stock for stock transaction

• AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

  3/16/2020

  Exceeds 2019 metrics with 166 REMS-certified facilities and 148 formulary approvals through December 31, greater than the year-end goals of 125 for each

• 

  AcelRx Buys Tetraphase Pharma for $14.4 Million

  3/16/2020

  AcelRx Pharmaceuticals, headquartered in Redwood City, California, is buying Watertown, Massachusetts-based TetraPhase Pharmaceuticals for $14.4 million.

• AcelRx to Announce Fourth Quarter 2019 Results on Monday, March 16th, 2020

  3/11/2020

  AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, announced that it will release fourth quarter and annual financial results before market open on Monday, March 16, 2020.

• AcelRx Announces Confirmed Timing of Department of Defense Milestone C Meeting for April

  3/10/2020

  DSUVIA procurement expected following completion of Milestone C meeting

• AcelRx Announces Agreement for an Investigator-Initiated Study of DSUVIA® in Patients Undergoing Spine Surgery

  3/6/2020

   AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced an agreement with Brigham and Women's Hospital for an investigator-initiated study led by Richard D. Urman MD, MBA,

• AcelRx Announces Year-End 2019 Metrics and Provides Corporate Updates

  1/13/2020

  Exceeds 2019 metrics with 166 REMS-certified facilities and 148 formulary approvals through December 31, greater than the year-end goals of 125 for each

• AcelRx Pharmaceuticals Announces Publication Analyzing Pooled Dosing and Efficacy Data on Sufentanil Sublingual 30 mcg Tablets

  11/13/2019

  AcelRx Pharmaceuticals, Inc. announced a publication analyzing pooled dosing and efficacy data from use of the sufentanil sublingual tablet 30 mcg among multiple demographic subgroups This data, published in the Journal of PeriAnesthesia Nursing, was analyzed to aid nurses in understanding the effectiveness and duration of action of SST 30 mcg in the management of moderate-to-severe acute pain across a variety of patient demographics.